{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:51:01Z","timestamp":1791355861470,"version":"4.3.1"},"reference-count":40,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,10,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the same entity, but controversy remains over whether CLL and SLL should be treated similarly. We assessed whether characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes and prognostic factors. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> We searched the electronic database for patients with CLL or SLL who presented to The University of Texas M.D. Anderson Cancer Center (Houston, TX) between 1985 and 2005. We reviewed patient records to determine presenting characteristics, treatment, and clinical outcomes. Cox models using training and validation sets of patients and resampling methods were used to develop a model predicting survival. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Among 2,126 consecutive CLL\/SLL patients, 312 (15%) had ALC less than 5 \u00d7 10<jats:sup>9<\/jats:sup>\/L. Patients with ALC less than 5 \u00d7 10<jats:sup>9<\/jats:sup>\/L had lower rates of cytogenetic abnormalities (P = .0002) and higher rates of CD38-positive results (P = .0002) and had mutated immunoglobulin heavy-chain variable region gene status (P = .034). Rates of response, survival, and failure-free survival (FFS) were not different among ALC groups. Regimens that included rituximab and a nucleoside analog were associated with superior rates of response and FFS compared with other therapies, irrespective of ALC. Deletion 17p or 6q with or without other cytogenetic abnormalities, age at least 60 years, \u03b2<jats:sub>2<\/jats:sub>-microglobulin at least 2 mg\/L, albumin less than 3.5 g\/dL, and creatinine at least 1.6 mg\/dL were each found to independently predict shorter survival and formed the basis of a scoring system. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Patients with CLL or SLL can be treated similarly. A new prognostic score is proposed. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.09.4508","type":"journal-article","created":{"date-parts":[[2007,10,9]],"date-time":"2007-10-09T22:24:24Z","timestamp":1191968664000},"page":"4648-4656","source":"Crossref","is-referenced-by-count":78,"title":["Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center"],"prefix":"10.1200","volume":"25","author":[{"given":"Apostolia M.","family":"Tsimberidou","sequence":"first","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McLaughlin","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Manning","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Lerner","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinh V.","family":"Mai","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma M.","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hess","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim-Anh","family":"Do","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil J.","family":"Freireich","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[{"name":"From the Departments of Leukemia, Biostatistics and Applied Mathematics, Lymphoma\/Myeloma, and Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","unstructured":"Muller-Hermelink HK, Catovsky D, Montserrat E, et al: Chronic lymphocytic leukemia\/small lymphocytic lymphoma, in Jaffe ES HN, Stein H, Wardiman JW (eds): Tumors of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumors . Lyon, France, IARC Press, pp 127,2001-130"},{"key":"R2","unstructured":"Freedman AS, Nadler LM: Non-Hodgkin's lymphomas, in Kufe DW, Pollock RE, Weichselbaum RR, et al (eds): Cancer Medicine  (ed 6), Hamilton, Ontario, Canada, BC Decker Inc, pp 2189,2003-2210"},{"key":"R3","unstructured":"Spertini O, Freedman AS, Belvin MP, et al: Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells. Leukemia 5:300,1991-308,"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V59.2.258.258"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00377.x"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198412063112303"},{"key":"R7","unstructured":"Rai K, Patel DV: Chronic lymphocytic leukemia, in Hoffman R, Benz EJ, Shaffil SJ, et al (eds): Hematology: Basic Principles and Practice (ed 3) . Philadelphia, PA, Churchill Livingstone, pp 1350,2000-1363"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.44"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.11.2878.2878"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1695.1695"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20264"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"R14","unstructured":"McLaughlin P, Hagemeister FB, Rodriguez MA, et al: Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27:37,2000-41,"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"R16","unstructured":"McLaughlin P, Liu N, Poindexter N, et al: Rituximab plus GM-CSF for indolent lymphoma. Ann Oncol 16:104,2005,  (suppl; abstr)"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.bloodjournal462219"},{"key":"R20","unstructured":"Montserrat E, Vinolas N, Reverter JC, et al: Natural history of chronic lymphocytic leukemia: On the progression and progression and prognosis of early clinical stages. Nouv Rev Fr Hematol 30:359,1988-361,"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Dighiero G. Guidelines for clinical management of chronic lymphocytic leukemia, in Faguet GB (ed): Contemporary Hematology: Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis and Management.  Totowa, NJ, Humana Press, pp 219,2004-240","DOI":"10.1007\/978-1-59259-412-2_12"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2455"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3612"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403242"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.6.1545.1545"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Molica S, Brugiatelli M, Callea V, et al: Comparison of younger versus older B-cell chronic lymphocytic leukemia patients for clinical presentation and prognosis: A retrospective study of 53 cases. Eur J Haematol 52:216,1994-221,","DOI":"10.1111\/j.1600-0609.1994.tb00648.x"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.2.448"},{"key":"R29","unstructured":"Keating MJ, Lerner S, Kantarjian H, et al: The serum b2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia. Blood 86:2412,1998,  (abstr)"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609054782"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023143"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.10.2146"},{"key":"R35","unstructured":"Hallek M, Langenmayer I, Nerl C, et al: Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 93:1732,1999-1737,"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4516"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.11.3452.3452"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1023"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050995"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Binet JL, Caligaris-Cappio F, Catovsky D, et al: Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107:859,2006-861,","DOI":"10.1182\/blood-2005-04-1677"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.09.4508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:16:37Z","timestamp":1653513397000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.09.4508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,10]]},"references-count":40,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2007,10,10]]}},"alternative-id":["10.1200\/JCO.2006.09.4508"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.09.4508","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,10]]}}}